[D]octors without Borders (Médecins Sans Frontières or MSF) will begin trials of three therapies starting next month in West Africa. Here’s how those trials will break down:
The French National Institute of Health and Medical Research (INSERM) will use the antiviral drug favipiravir in Guéckédou, Guinea.
The Antwerp Institute of Tropical Medicine (ITM) will use convalescent whole blood and plasma therapy [blood from Ebola survivors] at the Donka Ebola center in Conakry, Guinea.
The University of Oxford will lead, on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), a Wellcome Trust-funded trial of the antiviral drug brincidofovir at a site yet to be determined.